Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells

Gene Therapy
A Aartsma-RusJ C T van Deutekom

Abstract

As small molecule drugs for Duchenne muscular dystrophy (DMD), antisense oligonucleotides (AONs) have been shown to restore the disrupted reading frame of DMD transcripts by inducing specific exon skipping. This allows the synthesis of largely functional Becker muscular dystrophy (BMD)-like dystrophins and potential conversion of severe DMD into milder BMD phenotypes. Thus far we have used 2'-O-methyl phosphorothioate (2OMePS) AONs. Here, we assessed the skipping efficiencies of different AON analogs containing morpholino-phosphorodiamidate, locked nucleic acid (LNA) or peptide nucleic acid (PNA) backbones. In contrast to PNAs and morpholinos, LNAs have not yet been tested as splice modulators. Compared to the most effective 2OMePS AON directed at exon 46, the LNA induced higher skipping levels in myotubes from a human control (85 versus 20%) and an exon 45 deletion DMD patient (98 versus 75%). The morpholino-induced skipping levels were only 5-6%, whereas the PNA appeared to be ineffective. Further comparative analysis of LNA and 2OMePS AONs containing up to three mismatches revealed that LNAs, while inducing higher skipping efficiencies, show much less sequence specificity. This limitation increases the risk of adverse effect...Continue Reading

References

Jun 6, 1998·Nucleic Acids Research·L MologniC Gambacorti-Passerini
May 12, 2000·Biochimica Et Biophysica Acta·J Summerton
May 12, 2000·Biochimica Et Biophysica Acta·H J LarsenP E Nielsen
Jun 2, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A Ray, B Nordén
Oct 4, 2000·Nature Genetics·A Nasevicius, S C Ekker
Jul 27, 2001·Human Molecular Genetics·J C van DeutekomG J van Ommen
Jul 31, 2001·Genesis : the Journal of Genetics and Development·S C Ekker, J D Larson
Jul 31, 2001·Genesis : the Journal of Genetics and Development·P A Morcos
Feb 12, 2002·Bioorganic & Medicinal Chemistry·Christian J Leumann
Apr 3, 2002·Biochemistry·Dwaine A Braasch, David R Corey
Sep 11, 2002·Neuromuscular Disorders : NMD·Annemieke Aartsma-RusJudith C T van Deutekom
Nov 12, 2002·Nature Biotechnology·Peter SazaniRyszard Kole
Dec 25, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Thipparat SuwanmaneeRyszard Kole
Jan 14, 2003·Nature Structural Biology·Luca Cartegni, Adrian R Krainer
Apr 2, 2003·Human Molecular Genetics·Annemieke Aartsma-RusJudith C T van Deutekom
Jul 23, 2003·Human Molecular Genetics·Bianca L GebskiStephen D Wilton
Dec 19, 2003·American Journal of Human Genetics·Annemieke Aartsma-RusJudith C T van Deutekom

❮ Previous
Next ❯

Citations

Mar 24, 2009·Expert Reviews in Molecular Medicine·Paul J WhiteBen J Boyd
Apr 22, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hans HeemskerkJudith C T van Deutekom
Apr 21, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·HaiFang YinMatthew Ja Wood
Aug 2, 2011·Nature Reviews. Drug Discovery·Francesco Muntoni, Matthew J A Wood
Oct 27, 2006·Gene Therapy·K FosterJ G Dickson
Jun 21, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sue FletcherStephen D Wilton
Oct 31, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haifang YinMatthew Wood
Feb 15, 2008·Médecine sciences : M/S·Jean-Claude KaplanLuis Garcia
Jan 8, 2009·Oligonucleotides·John BaumanRyszard Kole
Aug 24, 2012·Mutagenesis·Reshat ReshatNigel J Gooderham
Dec 3, 2008·BMC Medical Genetics·Laura van VlietAnnemieke Aartsma-Rus
Dec 5, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yoichi NegishiYukihiko Aramaki
Feb 11, 2014·Nucleic Acid Therapeutics·Kavitha SivaMichela A Denti
Jan 2, 2014·Nucleic Acid Therapeutics·Yusuke Echigoya, Toshifumi Yokota
Aug 29, 2013·BioMed Research International·Yoshitsugu AokiMatthew J A Wood
Nov 1, 2013·Nucleic Acid Therapeutics·Peter JärverMichael J Gait
Mar 31, 2011·Future Medicinal Chemistry·Tsuyoshi YamamotoSatoshi Obika
Dec 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Qi Long LuTerence Partridge
Sep 17, 2014·Molecular Therapy. Nucleic Acids·Lorena Gallego-VillarLourdes R Desviat
May 16, 2014·Human Gene Therapy·Petra DistererBernard Khoo
Nov 26, 2014·Molecular Therapy. Nucleic Acids·Suzan M HammondSamir E L Andaloussi
Jan 3, 2015·Advanced Drug Delivery Reviews·Kelsey R BeaversCraig L Duvall
Jun 22, 2005·The Journal of Cell Biology·Rudy L JulianoDong Xu
Jun 9, 2007·Expert Opinion on Biological Therapy·Toshifumi YokotaKanneboyina Nagaraju
Dec 7, 2013·Expert Opinion on Biological Therapy·Susan JarminGeorge Dickson
Jul 14, 2010·Peptides·Yiqi SeowMatthew J A Wood
Oct 3, 2009·Annals of the New York Academy of Sciences·Hans HeemskerkAnnemieke Aartsma-Rus
Oct 28, 2006·Muscle & Nerve·Jerry R MendellR Rodney Howell
Feb 24, 2011·Pediatrics International : Official Journal of the Japan Pediatric Society·Shiho NakanoShigemi Kimura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.